The estimated Net Worth of Richard H Bagger is at least 1.5 千$ dollars as of 13 August 2020. Mr. Bagger owns over 10,000 units of Tonix Pharmaceuticals Corp stock worth over 1,500$ and over the last 4 years he sold TNXP stock worth over 0$. In addition, he makes 0$ as Director at Tonix Pharmaceuticals Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Bagger TNXP stock SEC Form 4 insiders trading
Richard has made over 1 trades of the Tonix Pharmaceuticals Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of TNXP stock worth 9,100$ on 13 August 2020.
The largest trade he's ever made was buying 10,000 units of Tonix Pharmaceuticals Corp stock on 13 August 2020 worth over 9,100$. On average, Richard trades about 1,667 units every 0 days since 2020. As of 13 August 2020 he still owns at least 10,000 units of Tonix Pharmaceuticals Corp stock.
You can see the complete history of Mr. Bagger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Bagger biography
Richard H. Bagger J.D. serves as Director of the Company. has been a Partner and Executive Director of Christie 55 Solutions, LLC, a New Jersey based consulting firm, since January 2020. Mr. Bagger has also been an Adjunct Faculty member at the Rutgers University Eagleton Institute since 2018. From 2012 through 2019, Mr. Bagger was Executive Vice President of Corporate Affairs and Market Access for Celgene Corporation (NASDAQ: CELG), a global biopharmaceutical company, as well as a member of its Executive Committee. From 1993 to 2010, Mr. Bagger held roles of increasing responsibility with Pfizer Inc. (NYSE: PFE), a global pharmaceutical company, and served as Senior Vice President, Worldwide Public Affairs and Policy, from 2006 to 2009. Prior to joining Pfizer, Mr. Bagger was Assistant General Counsel of Blue Cross and Blue Shield of New Jersey, a health insurer, and practiced law with the law firm of McCarter & English. Mr. Bagger served as Board Chair of the National Pharmaceutical Council for 2019 and is a member of the Board of Directors of the U.S. Chamber of Commerce. He is also on the advisory board for the Lerner Center for the Study of Pharmaceutical Management Issues at Rutgers University Business School. Mr. Bagger received an A.B. degree from Princeton University’s Woodrow Wilson School of Public and International Affairs and a J.D. degree from Rutgers University Law School.
How old is Richard Bagger?
Richard Bagger is 60, he's been the Director of Tonix Pharmaceuticals Corp since 2020. There are 8 older and 6 younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.
What's Richard Bagger's mailing address?
Richard's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM, NJ, 07928.
Insiders trading at Tonix Pharmaceuticals Corp
Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over 155,884$ worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth 3,399,062$ . The most active insiders traders include Ernest Mario、Seth Lederman、Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of 2,734$. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth 34,200$.
What does Tonix Pharmaceuticals Corp do?
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
What does Tonix Pharmaceuticals Corp's logo look like?
Complete history of Mr. Bagger stock trades at Tonix Pharmaceuticals Corp
Tonix Pharmaceuticals Corp executives and stock owners
Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:
-
Seth Lederman,
Chairman of the Board, President, Chief Executive Officer -
Dr. Seth Lederman M.D.,
Co-Founder, Pres, CEO & Chairman -
Dr. Seth Lederman,
Co-Founder, Pres, CEO & Chairman -
Dr. Gregory M. Sullivan M.D.,
Chief Medical Officer & Sec. -
Gregory Sullivan,
Secretary, Chief Medical Officer -
Bradley Saenger CPA, CPA,
CFO & Treasurer -
Bradley Saenger,
Chief Financial Officer, Treasurer -
Richard Bagger,
Director -
Herbert Harris,
Executive Vice President - Translational Medicine -
David Grange,
Independent Director -
Margaret Bell,
Independent Director -
James Treco,
Lead Independent Director -
Adeoye Olukotun,
Independent Director -
Daniel Goodman,
Independent Director -
Jessica Morris,
Chief Operating Officer -
Dr. Sina Bavari Ph.D.,
Exec. VP of Infectious Disease R&D -
Dr. Anthony Macaluso Ph.D.,
Exec. VP of Strategic Devel. -
Dr. Darryl Rideout Ph.D.,
Exec. VP of Experimental Chemistry -
Siobhan Fogarty B.Sc., M.Sc.,
Exec. VP of Product Devel. -
Dr. Bruce L. Daugherty M.B.A., Ph.D.,
Exec. VP of Research -
Dr. Herbert W. Harris M.D., Ph.D.,
Exec. VP of Translational Medicine -
Dr. R. Michael Gendreau,
Consultant -
Dr. Daniel J. Clauw M.D.,
Consultant -
Dr. Ronald R. Notvest,
Exec. VP of Commercial Planning and Devel. -
Jessica Edgar Morris,
Chief Operating Officer -
Charles E Iv Mather,
Director -
Ernest Mario,
Director -
John B Rhodes,
Director -
Samuel R Saks,
Director -
Patrick P Grace,
Director -
Bruce Daugherty,
See Remarks -
Stuart Davidson,
Director -
Donald J Kellerman,
See Remarks -
Leland Gershell,
CFO and Treasurer -
Carolyn E. Taylor,
Director -
Richard Newcomb Stillwell,
Director